bioAffinity Technologies, Inc. has received notification from the China National Intellectual Property Administration regarding the allowance of a patent application related to its noninvasive lung cancer diagnostic methods. This development is significant given China's substantial population of smokers, which contributes to the country's high rate of lung cancer. The patent, titled "System and Method for Determining Lung Health," involves the use of specific antibodies and the porphyrin TCPP to label cell populations in sputum, utilizing flow cytometry to detect lung cancer cells. This notification is part of bioAffinity's strategy to expand its proprietary diagnostic platform internationally.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。